Important August 25, 2025 Deadline Reminder: Kessler Topaz Meltzer & Check, LLP Reminds Hims & Hers Health, Inc. Investors of Securities Fraud Class Action Lawsuit
CONTACT KESSLER TOPAZ MELTZER & CHECK, LLP:
If you suffered Hims & Hers losses, you may CLICK HERE or copy and paste the following link into your browser: https://www.ktmc.com/new-cases/hims-hers-health-inc?utm_source=NewMediaWire&utm_medium=PR
You can also contact attorney Jonathan Naji, Esq. by calling (484) 270-1453 or by email at [email protected].
DEFENDANTS' ALLEGED MISCONDUCT:
The complaints allege that, throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the company's business, operations, and prospects. Specifically, Defendants failed to disclose to investors that: (1) Hims & Hers was engaged in the 'deceptive promotion and selling of illegitimate, knockoff versions of Wegovy that put patient safety at risk;' (2) as a result, there was a substantial risk that Hims & Hers' collaboration with Novo Nordisk would be terminated; and (3) that, as a result of the foregoing, Defendants' positive statements about the company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.
Please CLICK HERE to view our video or copy and paste this link into your browser: https://youtu.be/xuStgUOFgE8
THE LEAD PLAINTIFF PROCESS:
Hims & Hers investors may, no later than August 25, 2025, seek to be appointed as a lead plaintiff representative of the class through Kessler Topaz Meltzer & Check, LLP or other counsel, or may choose to do nothing and remain an absent class member. A lead plaintiff is a representative party who acts on behalf of all class members in directing the litigation. The lead plaintiff is usually the investor or small group of investors who have the largest financial interest and who are also adequate and typical of the proposed class of investors. The lead plaintiff selects counsel to represent the lead plaintiff and the class and these attorneys, if approved by the court, are lead or class counsel. Your ability to share in any recovery is not affected by the decision of whether or not to serve as a lead plaintiff.
Kessler Topaz Meltzer & Check, LLP encourages Hims & Hers investors who have suffered significant losses to contact the firm directly to acquire more information.
CLICK HERE TO SIGN UP FOR THE CASE OR GO TO: https://www.ktmc.com/new-cases/hims-hers-health-inc?utm_source=NewMediaWire&utm_medium=PR
ABOUT KESSLER TOPAZ MELTZER & CHECK, LLP:
Kessler Topaz Meltzer & Check, LLP prosecutes class actions in state and federal courts throughout the country and around the world. The firm has developed a global reputation for excellence and has recovered billions of dollars for victims of fraud and other corporate misconduct. All of our work is driven by a common goal: to protect investors, consumers, employees and others from fraud, abuse, misconduct and negligence by businesses and fiduciaries. The complaint in this action was not filed by Kessler Topaz Meltzer & Check, LLP. For more information about Kessler Topaz Meltzer & Check, LLP please visit www.ktmc.com.
CONTACT:
Kessler Topaz Meltzer & Check, LLP
Jonathan Naji, Esq.
(484) 270-1453
280 King of Prussia Road
Radnor, PA 19087
[email protected]
May be considered attorney advertising in certain jurisdictions. Past results do not guarantee future outcomes.
View the original release on www.newmediawire.com

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Business Insider
an hour ago
- Business Insider
Novo Nordisk Stock (NVO) Plunges 20% on Guidance Cut and CEO Appointment
Shares of Novo Nordisk (NVO) are down 20% after the European pharmaceutical giant lowered its full-year sales and profit guidance and announced a new CEO. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. The company said it now expects full-year sales growth of 8% to 14%, down from a previous target of 13% to 21%. In terms of profit, Novo Nordisk said that it expects annual growth of 10% to 16% versus the previously estimated target of 16% to 24%. Management said the outlook was being cut because of weaker growth expectations for its Wegovy weight-loss drug in the U.S. Novo Nordisk said it expects weaker sales of Wegovy and its Ozempic diabetes treatment in America during this year's second half. 'For Wegovy in the U.S., the sales outlook reflects the persistent use of compounded GLP-1s, slower-than-expected market expansion and competition,' said the company in a news release. New CEO The lowered guidance comes as Novo Nordisk struggles to keep pace with its U.S. rival Eli Lilly (LLY), the maker of competing obesity and diabetes drugs Mounjaro and Zepbound. This is the second time in recent months that Novo Nordisk has lowered its guidance. The company previously downgraded its 2025 outlook in May as it reported lower-than-expected first-quarter sales. At the same time, the Danish pharmaceutical company announced the appointment of Maziar Mike Doustdar, an internal candidate, as its new CEO. The new CEO appointment follows the surprise ousting of Lars Fruergaard Jørgensen in May of this year. The downwardly revised guidance and new CEO appointment come ahead of Novo Nordisk's second-quarter financial results that are scheduled to be released on Aug. 6. NVO stock is down 36% this year. Is NVO Stock a Buy? average NVO price target of $81.33 implies 48.20% upside from current levels.
Yahoo
an hour ago
- Yahoo
NOV Inc (NOV) Q2 2025 Earnings Call Highlights: Navigating Market Challenges with Strategic ...
Revenue: $2.2 billion for Q2 2025, up 4% sequentially, down 1% year-over-year. Net Income: $108 million or $0.29 per fully diluted share. Adjusted EBITDA: $252 million, representing 11.5% of sales. Free Cash Flow: $108 million generated in Q2 2025. Share Repurchase: 10.9 million shares repurchased for $150 million in the first half of 2025. Dividends: Quarterly base dividend of $0.075 per share and a supplemental dividend of $0.21 per share, totaling $135 million year-to-date. Tariff Expense: $11 million in Q2 2025, expected to rise to $20-$25 million in Q3 and $25-$30 million in Q4. Energy Products and Services Revenue: $1.03 billion, a 2% decrease year-over-year. Energy Equipment Revenue: $1.21 billion, nearly unchanged year-over-year. Energy Equipment EBITDA: $158 million, with a 13.1% margin. Working Capital Improvement: 300 basis point improvement year-over-year as a percentage of revenue. Tax Rate: Expected full-year tax rate between 26% and 28%. Warning! GuruFocus has detected 10 Warning Signs with GBNXF. Release Date: July 29, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points NOV Inc (NYSE:NOV) reported a 4% sequential increase in revenue for the second quarter of 2025, reaching $2.2 billion. The Energy Equipment segment achieved its 12th consecutive quarter of year-over-year margin expansion. NOV Inc (NYSE:NOV) generated $108 million in free cash flow during the quarter, converting 83% of EBITDA to free cash flow over the last 12 months. The company repurchased 10.9 million shares for $150 million in the first half of 2025, returning $602 million to shareholders through buybacks and dividends. NOV Inc (NYSE:NOV) is focused on structural cost reduction and process improvement, expecting to remove over $100 million in annual costs by the end of 2026. Negative Points Global drilling activity declined by 6% sequentially, with North American exploration and production companies curtailing short-cycle activity. Pricing pressure is intensifying, with international conventional activity easing and Saudi Arabia suspending additional onshore rigs. Tariff-related and inflationary cost pressures compressed segment margins, with tariff expenses expected to rise in the coming quarters. The Energy Products and Services segment experienced a 20% year-over-year decline in product sales due to market uncertainty and reduced global activity. NOV Inc (NYSE:NOV) anticipates a challenging remainder of 2025, with expectations of North American shale activity drifting modestly lower and global drilling activity slowing further. Q & A Highlights Q: Clay, given the recent changes and challenges, how are you thinking about where margins might bottom in the next few quarters, and what could drive them back up? A: Clay Williams, Chairman and CEO, explained that while margins have been pressured by factors like OPEC+ production increases and tariff impacts, NOV is focused on cost reduction initiatives. He is optimistic that these efforts will stabilize margins in the second half of the year and set the stage for recovery in 2026, driven by increased offshore activity and demand for NOV's technologies. Q: What are the key indicators you are watching to signal a market turnaround in the next few quarters? A: Clay Williams noted that while current market conditions are challenging due to commodity price pressures and OPEC's actions, he expects signs of recovery as offshore drillers prepare for increased activity in 2026. He anticipates more inbound calls for equipment projects and spare parts, indicating a market turnaround. Q: Can you provide an update on NOV's cash generation and working capital expectations for the rest of the year? A: Rodney Reed, CFO, highlighted that NOV has achieved strong free cash flow conversion, with working capital as a percentage of revenue improving by 300 basis points year-on-year. For the second half of the year, they expect CapEx to be consistent with last year and working capital as a percentage of sales to be between 27% and 29%, leading to a healthy free cash flow outlook. Q: With the cost reduction steps taken, what size market is NOV preparing for, and what further cost initiatives might be available? A: Clay Williams stated that NOV is preparing for a larger market, driven by international unconventional and deepwater demand. While current market conditions are challenging, NOV is focusing on efficiency improvements and facility consolidations. Jose Bayardo, COO, added that these efforts are part of a long-term strategy to capitalize on market shifts rather than a downsizing due to lower activity expectations. Q: Can you discuss the adoption rate of NOV's automation and digital technologies, particularly in offshore markets? A: Jose Bayardo shared that NOV's automation and digital technologies, such as the NOVOS platform and robotics systems, are seeing strong market traction. The company has sold 220 NOVOS systems, with 134 installed, and has a growing pipeline for robotics systems. Digital product revenue is up 25% year-over-year, indicating robust adoption and future growth potential. For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus.


Business Insider
an hour ago
- Business Insider
RBC Capital Reaffirms Their Hold Rating on IAMGOLD (IAG)
In a report released on July 28, Michael Siperco from RBC Capital maintained a Hold rating on IAMGOLD, with a price target of $9.00. The company's shares closed yesterday at $6.97. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Siperco covers the Basic Materials sector, focusing on stocks such as Torex Gold Resources, Orla Mining, and Equinox Gold. According to TipRanks, Siperco has an average return of 22.5% and a 64.67% success rate on recommended stocks. In addition to RBC Capital, IAMGOLD also received a Hold from TR | OpenAI – 4o's Orla Bullionna in a report issued on July 22. However, on July 28, Bank of America Securities reiterated a Buy rating on IAMGOLD (NYSE: IAG). Based on IAMGOLD's latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $477.1 million and a net profit of $39.7 million. In comparison, last year the company earned a revenue of $338.9 million and had a net profit of $54.8 million Based on the recent corporate insider activity of 30 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of IAG in relation to earlier this year.